sandostatine long acting repeatable 20 mg pulver und lösungsmittel zur herstellung einer injektionssuspension
novartis pharma - octreotid-acetat - pulver und lösungsmittel zur herstellung einer injektionssuspension - 20 mg - octreotid-acetat 22.4 mg - octreotide
monlutenca 40 gbq/ml radiopharmac. precursor sol. i.v. vial
monlutenca 40 gbq/ml radiofarmac. uitgangsstof opl. i.v. flac.
monlutenca 40 gbq/ml sol. précurseur radiopham. i.v. flac.
sandostatine long acting repeatable 20 mg (abacus medicine) inj. susp. (pwdr. + solv.) i.m. pre-filled syr. vial
sandostatine long acting repeatable 20 mg (abacus medicine) inj. susp. (pdr. + oplosm.) i.m. voorgev. spuit flac.
sandostatine long acting repeatable 20 mg (abacus medicine) susp. inj. (pdr. + solv.) i.m. ser. préremplie flac.
sandostatine long acting repeatable 30 mg (abacus medicine) inj. susp. (pwdr. + solv.) i.m. pre-filled syr. vial
sandostatine long acting repeatable 30 mg (abacus medicine) inj. susp. (pdr. + oplosm.) i.m. voorgev. spuit flac.
sandostatine long acting repeatable 30 mg (abacus medicine) susp. inj. (pdr. + solv.) i.m. ser. préremplie flac.